Palvella Therapeutics, Inc.
PVLA
$50.13
-$3.29-6.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -28.38M | -23.08M | -17.43M | 7.06M | 11.00M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.50M | 8.16M | 6.79M | -17.08M | -17.67M |
| Change in Net Operating Assets | -1.45M | -1.59M | -193.00K | 2.15M | -1.58M |
| Cash from Operations | -20.34M | -16.51M | -10.84M | -7.87M | -8.25M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 8.43M | 18.43M | 18.43M | 17.43M | 15.00M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 60.42M | 60.07M | 60.00M | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 7.49M | 7.39M | 8.66M | -129.00K | -108.00K |
| Cash from Financing | 76.34M | 85.89M | 87.09M | 17.30M | 14.89M |
| Foreign Exchange rate Adjustments | -111.00K | -3.00K | 3.00K | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 55.90M | 69.38M | 76.25M | 9.43M | 6.64M |